Recognition, Product Enhancement, Marketing Approval, Upcoming Events, and Quarterly Earnings - Research Reports on Abbott, Illumina, Thermo Fisher, Intercept and Stryker

NEW YORK, October 22, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Abbott Laboratories (NYSE: ABT), Illumina Inc. (NASDAQ: ILMN), Thermo Fisher Scientific, Inc. (NYSE: TMO), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) and Stryker Corporation (NYSE: SYK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7389-100free.

--
Abbott Laboratories Research Reports
On October 16, 2014, Abbott Laboratories (Abbott) announced that it has achieved 12th rank in the journal Science's latest annual list of 20 best employers in the pharmaceutical and related industries. Also, this marks the eleventh time that Abbott has been included in the journal's annual ranking, which is based on the views of working scientists and identifies companies with the best reputations as employers. "At Abbott, we believe that good health is the starting point for everything that is possible in life, and carrying out that mission begins with our scientists," said John Frels, Ph.D., co-Chair of Abbott's Scientific Governing Board. The full research reports on Abbott are available to download free of charge at:

http://www.analystsreview.com/Oct-22-2014/ABT/report.pdf

--
Illumina Inc. Research Reports
On October 17, 2014, Illumina Inc. (Illumina) announced the launch of new reagent kits for the HiSeq XTM Ten and HiSeq® 2500 Sequencing Systems to offer improved performance for high throughput sequencing. According to the Company, the new kits boost the power and efficiency of HiSeq Systems and expand the range of possibilities available to researchers using Illumina sequencing technologies by offering superior data quality on the HiSeq X Ten System and longer read lengths on the HiSeq 2500 System. The HiSeq X HD v2 Reagent Kits and the HiSeq Rapid v2 Reagent Kits will begin shipping in November 2014. The full research reports on Illumina are available to download free of charge at:

http://www.analystsreview.com/Oct-22-2014/ILMN/report.pdf

--
Thermo Fisher Scientific, Inc. Research Reports
On October 16, 2014, Thermo Fisher Scientific, Inc. (Thermo Fisher) announced the successful CE-IVD registration of its new Ion PGM Dx System for sale in European countries. Thermo Fisher informed that the Ion PGM Dx System was developed using the proven Ion Torrent next generation sequencing (NGS) technology, which is currently used to produce hundreds of thousands of tests in clinical research laboratories each year to uncover meaningful genetic information for a range of human conditions. "The CE-IVD registration of the Ion PGM Dx System will enable European clinical laboratories to more easily develop and implement new next-generation sequencing diagnostic assays in accordance with the European Directive on In Vitro Diagnostic Medical Devices," said Mark Stevenson, President of Life Sciences Solutions at Thermo Fisher. The full research reports on Thermo Fisher are available to download free of charge at:

http://www.analystsreview.com/Oct-22-2014/TMO/report.pdf

--
Intercept Pharmaceuticals, Inc. Research Reports
On October 8, 2014, Intercept Pharmaceuticals, Inc. (Intercept) announced upcoming presentations of data at the upcoming American Academy for the Study of Liver Diseases (AASLD) Annual Meeting (the Liver Meeting®), which will be held in Boston, Massachusetts from November 7-11, 2014. Intercept informed that its lead product candidate Obeticholic acid (OCA) is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR) in development for primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and other chronic liver and intestinal diseases. The Company is also developing the preclinical product candidates INT-777 (an agonist of TGR5, a bile acid receptor) and INT-767 (a dual FXR/TGR5 agonist). The full research reports on Intercept are available to download free of charge at:

http://www.analystsreview.com/Oct-22-2014/ICPT/report.pdf

--
Stryker Corporation Research Reports
On October 16, 2014, Stryker Corporation (Stryker) announced its Q3 2014 financial results. The Company reported that its net sales during the quarter surged 11.1% YoY to $2.4 billion, helped by increased unit volume and changes in product mix as well as acquisitions. Stryker's reported that net income in Q3 2014 declined to $57 million or $0.16 per share, from $103 million or $0.27 per share in Q3 2013. Stryker's reported net income included certain one-time charges including those related to Rejuvenate, ABG II and Neptune recalls, tax impacts related to the establishment of the European regional headquarters and a planned cash repatriation, acquisition related charges, among others. Excluding those charges, the Company earned $1.15 per diluted share in Q3 2014, beating the average estimate of $1.14 per share in a Reuters poll of analysts. Looking ahead, Stryker expects full-year 2014 adjusted diluted EPS to be at low end of the previously disclosed range of $4.75 to $4.80. The full research reports on Stryker are available to download free of charge at:

http://www.analystsreview.com/Oct-22-2014/SYK/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED